↓ Skip to main content

Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies

Overview of attention for article published in Neuropsychiatric Disease and Treatment, November 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news
3 news outlets
twitter
5 tweeters
facebook
2 Facebook pages

Citations

dimensions_citation
51 Dimensions

Readers on

mendeley
111 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies
Published in
Neuropsychiatric Disease and Treatment, November 2016
DOI 10.2147/ndt.s117146
Pubmed ID
Authors

Yu Han, Jianjun Chen, Dezhi Zou, Peng Zheng, Qi Li, Haiyang Wang, Pengfei Li, Xinyu Zhou, Yuqing Zhang, Yuyun Liu, Peng Xie

Abstract

An increasing number of studies are reporting that ketamine could be treated as a novel antidepressant for major depressive disorder (MDD). Therefore, we performed this meta-analysis to comprehensively and systematically assess the efficacy of ketamine for treating patients with MDD. Randomized, double-blind, placebo-controlled studies on ketamine versus placebo for treating MDD were searched up to April 2016 in medical databases (PubMed, CCTR, Web of Science, Embase, CBM-disc, and CNKI). Three treatment time points (24 and 72 h, and day 7) were chosen. Response and remission rates were the main outcomes. The random effects model was used. An intention-to-treat analysis was conducted. Nine high-quality studies that included 368 patients were selected to compare the efficacy of ketamine to placebo. The therapeutic effects of ketamine at 24 and 72 h, and day 7 were found to be significantly better than placebo. Response and remission rates in the ketamine group at 24 and 72 h, and day 7 were 52.2% and 20.6%; 47.9% and 23.8%; and 39.8% and 26.2%, respectively. No significant heterogeneity existed, and the Egger's test showed no publication bias. These results indicated that ketamine could yield a good efficacy in the rapid treatment of MDD. Future large-scale clinical studies are needed to confirm our results and investigate the mid- and long-term efficacy of ketamine in treating MDD.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 111 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 <1%
Unknown 110 99%

Demographic breakdown

Readers by professional status Count As %
Student > Master 17 15%
Student > Bachelor 15 14%
Researcher 14 13%
Student > Ph. D. Student 14 13%
Student > Doctoral Student 8 7%
Other 21 19%
Unknown 22 20%
Readers by discipline Count As %
Medicine and Dentistry 26 23%
Neuroscience 20 18%
Psychology 17 15%
Agricultural and Biological Sciences 6 5%
Social Sciences 5 5%
Other 12 11%
Unknown 25 23%

Attention Score in Context

This research output has an Altmetric Attention Score of 35. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 September 2019.
All research outputs
#628,983
of 15,839,793 outputs
Outputs from Neuropsychiatric Disease and Treatment
#73
of 2,571 outputs
Outputs of similar age
#19,231
of 290,323 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#6
of 77 outputs
Altmetric has tracked 15,839,793 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,571 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 290,323 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 77 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.